Genetic Analysis of Alzheimer’s Disease Progression in Clinical Trials
1:30 pm - Wednesday 4th February 2026
- Applying AI powered genome scans to uncover genetic modifiers of disease tempo and enable tighter trial designs and quicker read outs
- Mining longevity and centenarian genomes for protective variants to reveal resilience pathways, offering novel, lower risk targets to slow progression
- Incorporating C9orf72 and other cross disease variants into baseline panels to delineate molecular subtypes, reducing heterogeneity and boosting drug effect signals
